MA29015B1 - Agents de liaison specifiques de l'angiopoietine-2 - Google Patents

Agents de liaison specifiques de l'angiopoietine-2

Info

Publication number
MA29015B1
MA29015B1 MA29892A MA29892A MA29015B1 MA 29015 B1 MA29015 B1 MA 29015B1 MA 29892 A MA29892 A MA 29892A MA 29892 A MA29892 A MA 29892A MA 29015 B1 MA29015 B1 MA 29015B1
Authority
MA
Morocco
Prior art keywords
angiopoietin
specific binding
binding agents
agents
specific
Prior art date
Application number
MA29892A
Other languages
English (en)
French (fr)
Inventor
Jonathon Daniel Oliner
Kevin Graham
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA29015B1 publication Critical patent/MA29015B1/fr

Links

MA29892A 2004-10-19 2007-05-11 Agents de liaison specifiques de l'angiopoietine-2 MA29015B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents

Publications (1)

Publication Number Publication Date
MA29015B1 true MA29015B1 (fr) 2007-11-01

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29892A MA29015B1 (fr) 2004-10-19 2007-05-11 Agents de liaison specifiques de l'angiopoietine-2

Country Status (10)

Country Link
JP (2) JP2008520188A (pt)
CN (1) CN101495513B (pt)
BR (1) BRPI0518209A (pt)
EA (1) EA011866B1 (pt)
IL (1) IL182279A0 (pt)
MA (1) MA29015B1 (pt)
MX (1) MX2007004247A (pt)
RU (2) RU2404992C2 (pt)
SG (1) SG156668A1 (pt)
ZA (1) ZA200704020B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
DK2760471T3 (en) * 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
KR102063028B1 (ko) * 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
CN106512006A (zh) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用
CN106075448A (zh) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN109096368B (zh) * 2018-09-30 2021-07-20 华南理工大学 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
US20220204603A1 (en) * 2019-02-25 2022-06-30 Pharmabcine Inc. Anti-ang2 antibody and use thereof
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514434A (en) * 1999-03-26 2003-11-28 Univ California Modulation of vascular permeability by means of TIE2 receptor activators
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
PT1292335E (pt) * 2000-06-23 2007-08-13 Bayer Schering Pharma Ag Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii)
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
CA2473970C (en) * 2001-10-12 2013-05-28 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2

Also Published As

Publication number Publication date
IL182279A0 (en) 2007-07-24
RU2007118670A (ru) 2008-12-27
BRPI0518209A (pt) 2008-11-04
SG156668A1 (en) 2009-11-26
EA200700876A1 (ru) 2007-10-26
RU2404992C2 (ru) 2010-11-27
ZA200704020B (en) 2008-06-25
CN101495513B (zh) 2014-08-06
CN101495513A (zh) 2009-07-29
RU2010132956A (ru) 2012-02-10
EA011866B1 (ru) 2009-06-30
MX2007004247A (es) 2007-06-12
JP2011207882A (ja) 2011-10-20
JP2008520188A (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
NO20041907L (no) Angiopoietin-2 spesifikke bindinsmidler
EP1819385A4 (en) NEEDLE ACQUISITION MECHANISMS
SMT202000607T1 (it) Proteine leganti l'interleuchina-13
EP1789709A4 (en) STOPCOCK
EP1896040A4 (en) Phosphoramidate alkylator PRODRUGS
EP1621603A4 (en) DETERGENT COMPOSITION
EP1746141A4 (en) THICKENER
EP1827473A4 (en) MODULATOR OF ALPHA SYNNUCLEINE TOXICITY
FR2871145B1 (fr) Distributeur d'applicateurs
FR2875398B1 (fr) Implant articulaire d'interposition
EP1714656A4 (en) ED-71 preparation
EP1741218A4 (en) IMPROVED EXTENSION MOBILITY
MA28812B1 (fr) Combinaisons d'epothilone
FR2879635B1 (fr) Connecteur d'ossature
EP1704857A4 (en) ABCA1 STABILISATOR
IL190045A0 (en) Use of c3-c10 17 alfa-esters of 9,11-dehydrocortexolone as anti-gonadotrophic agents
FR2853380B1 (fr) Articulation elastique
EP1674486A4 (en) AFFINITY RESIN
EP1819722A4 (en) MODULATION OF OVULATION
GB2409587B (en) 'Kwicap'
GB0510474D0 (en) Q's vaginometer
EP1756276A4 (en) KRUST ANIMAL EXPRESSION VECTOR
FR2878004B3 (fr) Ferrure d'angle
FR2852042B1 (fr) Piece d'aretier
ITSV20040008A1 (it) Dottor "g"